IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The study will be conducted at 15-20 US centers in a randomized, placebo-controlled,
double-blind fashion. Enrollees will be hospitalized sickle cell disease (SCD) patients
at-risk for acute chest syndrome (ACS) based on the presence of vaso-occlusive crisis (VOC),
fever (T ≥38.0°C) and serum sPLA2 concentration ≥50 ng/mL.